Of those physicians who currently prescribe ACE inhibitors/ARBs to low-risk patients, 94% (157/162 endocrinologists and 179/196 PCPs) noted they would increase the dose of ACE inhibitors/ARBs in type 2 diabetes mellitus patients at an increased risk of diabetic kidney disease. The gene discussed is ACE; the disease is type 2 diabetes mellitus.